JP2023546565A5 - - Google Patents

Info

Publication number
JP2023546565A5
JP2023546565A5 JP2023521833A JP2023521833A JP2023546565A5 JP 2023546565 A5 JP2023546565 A5 JP 2023546565A5 JP 2023521833 A JP2023521833 A JP 2023521833A JP 2023521833 A JP2023521833 A JP 2023521833A JP 2023546565 A5 JP2023546565 A5 JP 2023546565A5
Authority
JP
Japan
Prior art keywords
compound according
group
optionally substituted
pharmaceutical composition
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023521833A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023546565A (ja
JP7699205B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/055608 external-priority patent/WO2022086958A1/en
Publication of JP2023546565A publication Critical patent/JP2023546565A/ja
Publication of JP2023546565A5 publication Critical patent/JP2023546565A5/ja
Application granted granted Critical
Publication of JP7699205B2 publication Critical patent/JP7699205B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023521833A 2020-10-21 2021-10-19 抗ウイルスプロドラッグ化合物 Active JP7699205B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063094728P 2020-10-21 2020-10-21
US63/094,728 2020-10-21
PCT/US2021/055608 WO2022086958A1 (en) 2020-10-21 2021-10-19 Antiviral prodrug compounds

Publications (3)

Publication Number Publication Date
JP2023546565A JP2023546565A (ja) 2023-11-06
JP2023546565A5 true JP2023546565A5 (https=) 2024-10-28
JP7699205B2 JP7699205B2 (ja) 2025-06-26

Family

ID=81290062

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023521833A Active JP7699205B2 (ja) 2020-10-21 2021-10-19 抗ウイルスプロドラッグ化合物

Country Status (4)

Country Link
US (1) US20230391807A1 (https=)
EP (1) EP4232456A4 (https=)
JP (1) JP7699205B2 (https=)
WO (1) WO2022086958A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102708995B1 (ko) 2018-01-10 2024-09-23 누코리온 파마슈티컬스, 인코포레이티드. 포스포르(포스포론)아미다타세탈 및 포스프(온)아탈세탈 화합물
MX2022000573A (es) 2019-07-17 2022-02-10 Nucorion Pharmaceuticals Inc Compuestos ciclicos de desoxirribonucleotido.
WO2021216431A1 (en) 2020-04-21 2021-10-28 Ligand Pharmaceuticals, Inc. Benzyloxy phosph(on)ate compounds
CN119080837B (zh) * 2024-11-07 2025-03-11 上海柯君医药科技有限公司 一种抗病毒药物及其用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3027279A1 (de) * 1980-07-18 1982-05-06 Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz Substituierte adenosin-3',5'-phosphorsaeurebenzyltriester, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
JP4902958B2 (ja) * 2002-06-07 2012-03-21 ユニバーシテール・メディッシュ・セントラム・ユトレヒト ｃＡＭＰによって直接活性化される交換タンパク質（Ｅｐａｃ）の活性をモジュレートするための新規な化合物
WO2007027248A2 (en) * 2005-05-16 2007-03-08 Valeant Research & Development 3', 5' - cyclic nucleoside analogues for treatment of hcv
US8173621B2 (en) * 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
US9296778B2 (en) * 2012-05-22 2016-03-29 Idenix Pharmaceuticals, Inc. 3′,5′-cyclic phosphate prodrugs for HCV infection
US9765107B2 (en) * 2013-06-18 2017-09-19 Merck Sharp & Dohme Corp. Cyclic phosphonate substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
US10202411B2 (en) * 2014-04-16 2019-02-12 Idenix Pharmaceuticals Llc 3′-substituted methyl or alkynyl nucleosides nucleotides for the treatment of HCV
EP3471738A4 (en) * 2016-06-20 2020-01-01 Merck Sharp & Dohme Corp. CYCLIC PHOSPHONATE-SUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHOD FOR USE THEREOF FOR TREATING VIRUS DISEASES
US20210038628A1 (en) * 2018-03-02 2021-02-11 January Therapeutics, Inc. Nanoparticle compositions
MX2021012894A (es) * 2019-04-22 2021-11-17 Ligand Pharm Inc Compuestos ciclicos de fosfato.

Similar Documents

Publication Publication Date Title
JP2023546565A5 (https=)
ES2521672T3 (es) Formulaciones farmacéuticas para el tratamiento del cáncer
CA1298200C (en) Process for producing a synergistic combination of amantadine and selegiline
JP2011093923A (ja) 点眼剤
RU2007116119A (ru) Производные циклоспорина, замещенные 3-эфиром и 3-тиоэфиром, для лечения и профилактики инфекционного гепатита с
JP2022529321A5 (https=)
JP2002539128A5 (https=)
EA200602130A1 (ru) Замещенные арилацилтиомочевины и родственные соединения; ингибиторы репликации вирусов
JP2022527556A5 (https=)
JP2021521118A5 (https=)
JP7600282B2 (ja) ５′－アデノシン二リン酸リボース（ａｄｐｒ）の使用方法
JPH09508641A (ja) アンギオテンシン▲ｉｉ▼拮抗薬による正常眼圧緑内障の治療
JP2022539185A5 (https=)
JP2019515040A5 (https=)
JP2002525318A (ja) 眼、耳および鼻治療用の抗生物質組成物
JP2024520132A5 (https=)
BR0314695A (pt) Composto, processo para preparar um composto, processo para preparar um estereoisÈmero de um composto, composição para o tratamento de doenças virais, e, composição para o tratamento da hepatite b
WO2016171152A1 (ja) 角膜障害の治療剤、改善剤または予防剤
JP2023502053A5 (https=)
RU2491931C2 (ru) Способы лечения тревоги
JP2022534420A5 (https=)
JPH1036365A5 (https=)
CN1160081C (zh) 用hiv蛋白酶抑制剂因地那夫和逆转录酶抑制剂3tc,以及任选的azt、ddi或ddc,对hiv感染进行组合治疗
RU2008112181A (ru) Применение конденсированных производных имидазола для лечения заболеваний, опосредованных рецептором ccr3
JP6509244B2 (ja) 水晶体硬化抑制剤